

✓  
Please cancel Claim 11, 12, 14, 21, 26, 27 and 30-33

Please amend the claims as follows:

C1  
SUB  
ET  
10. (Twice amended) An implant for controlled, sustained drug release comprising:  
a pharmacologically acceptable biodegradable polymer which is degraded at the site  
of implantation, wherein said biodegradable polymer comprises at least about 20 weight  
percent of the implant;  
a first therapeutically active agent at a concentration from 10 to 50 weight percent of  
the implant;  
a release modulator comprising hydroxypropylmethylcellulose at a concentration  
from 10 to 50 weight percent of the implant;  
wherein said implant is an anhydrous solid structure which is degraded at the site of  
implantation and releases said first therapeutically active agent within a therapeutic dosage  
which does not vary by more than about 100% for a period of at least about 3 days after  
implantation.

C2  
15. (Amended) An implant according to Claim 10, wherein said release modulator  
further comprises a second therapeutically active agent.

16. (Amended) An implant according to Claim 15, wherein said first therapeutically  
active agent is a steroid and said second therapeutically active agent is a water soluble antibiotic.

17. (Amended) An implant according to Claim 15, wherein said first therapeutically  
active agent is a non-steroidal antiinflammatory drug and said second therapeutically active agent  
is a water soluble antibiotic.

C3  
19. (Amended) An implant for controlled, sustained drug release comprising:  
poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight  
percent of the implant;  
a therapeutically active antiinflammatory drug at a concentration from 10 to 50  
weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which releases said therapeutically active antiinflammatory drug within a therapeutic dosage that does not vary by more than about 100% for a period of at least about 3 days.

C3  
cont.  
20. (Amended) An implant for controlled, sustained drug release comprising:  
poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active steroid at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which is degraded at the site of implantation and releases said therapeutically active steroid within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

23. (Amended) An implant according to Claim 20, wherein said release modulator further comprises a second therapeutically active agent.

24. (Amended) An implant according to Claim 23, wherein said second therapeutically active agent is a water soluble antibiotic.

C4  
25. (Amended) An implant for controlled, sustained drug release comprising:  
poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active non-steroidal antiinflammatory drug at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;